Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for XXXX in diabetes mellitus.

@entity1 @entity970 @entity66 @entity968 @entity755 @entity1723 @entity165 @entity453 @entity65 @entity4288
Several groups have published results from clinical studies supporting the involvement of anti-modified LDL antibodies as risk factors for the initiation or progression of @entity65 . However, the data published so far are judged inconclusive because of several contradictory observations concerning the correlation between clinical evidence of @entity4288 and the levels of antibodies to oxidized LDL (oxLDL Ab). We have previously reported that oxLDL Ab exist both in free form and as antigen-antibody complexes (LDL-IC) in @entity1 with @entity1723 ( @entity1723 ). The presence of LDL-IC in @entity1723 @entity1 has important implications: it may interfere with the assay of oxLDL antibodies and the levels of LDL-IC may correlate better with the development of @entity4288 than the levels of free oxLDL antibodies. To clarify these questions baseline samples collected from 49 @entity1723 @entity1 , who subsequently developed @entity453 ( @entity453 ) during an 8-year follow-up period, were compared to baseline samples from 49 age-, sex-, and duration-matched control @entity1723 subjects who remained free of clinical @entity453 during an identical follow-up period. The levels of free oxLDL antibody were significantly lower in the @entity1 who developed @entity453 . The same @entity1 had significantly higher concentrations of total @entity165 , @entity755 , and IgA in immune complex-enriched @entity968 ( @entity970 ) precipitates. The concentration of IgG was also higher in @entity970 precipitates from @entity1 who developed @entity453 , but did not reach statistical significance. This indicates that @entity1 who develop @entity453 had higher levels of circulating LDL-IC, a fact that could not be deduced from the measurement of free oxLDL antibody concentrations. A linear regression analysis of the correlation between the concentrations of total @entity165 in @entity970 precipitates, taken as a surrogate measurement of @entity970 -precipitated oxLDL-IC, and the concentration of free oxLDL antibody in serum showed a statistically significant negative correlation (r = -0.229, P = 0. 024). Our results support the conclusion that oxLDL-IC may be a risk factor for the development of @entity66 in @entity1723 @entity1 . We also have demonstrated that circulating oxLDL-IC interfere with the assay of free oxLDL antibodies.
